Retigabine – positive results in Phase III study

Results presented at the Annual Meeting of the American Epilepsy Society in Seattle December 6 demonstrate that Retigabine as an adjunctive treatment resulted in statistically significant reduction of seizures and that the response dose-dependent. The study (RESTORE 2) is a randomized, double- blind, placebo-controlled Phase III study (600mg and 900 mg) with the aim to compare Retigabine versus placebo in patients on antiepileptic drug therapy.

Retigabine comprises a new way of affecting potassium channels in the central nervous system.
It has been documented to treat epilepsy and has a different mechanism of action compared to current antiepileptic therapies. According to GlaxoSmithKline and Valeant, the registration application for the first indication, epilepsy, is expected to be submitted early 2009 in both the U.S. and in Europe.